Synthesis and in vitro cytotoxicity profile of the R-enantiomer of 3,4-dihydroxymethamphetamine (R-(-)-HHMA): Comparison with related catecholamines

Chemical Research in Toxicology

Volumn 23, Issue 1, 2010, Pages 211-219

  Felim, Anne ^a   Herrera, Guadalupe ^b   Neudörffer, Anne ^a   Blanco, Manuel ^b   O'Connor, José Enrique ^b   Largeron, Martine ^a  

^a UNIVERSITÉ PARIS DESCARTES   (France)

^b CENTRO DE INVESTIGACIÓN PRÍNCIPE FELIPE   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

3,4 DIHYDROXYMETHAMPHETAMINE; 3,4 METHYLENEDIOXYMETHAMPHETAMINE; 5 (N ACETYLCYSTEIN S YL) N METHYL R METHYLDOPAMINE; CATECHOL; CATECHOLAMINE; LEVODOPA; PROPIDIUM IODIDE; QUINONE DERIVATIVE; REACTIVE OXYGEN METABOLITE; UNCLASSIFIED DRUG;

ARTICLE; BIOTRANSFORMATION; CELL DEATH; CHIRALITY; CYTOTOXICITY; ENANTIOMER; ESCHERICHIA COLI; FLOW CYTOMETRY; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; METABOLITE; NEUROBLASTOMA; NEUROTOXICITY; OXIDATION REDUCTION REACTION; OXIDATIVE STRESS; RACEMIC MIXTURE; STEREOCHEMISTRY; SYNTHESIS;

CATECHOLAMINES; CELL LINE, TUMOR; DEOXYEPINEPHRINE; FLOW CYTOMETRY; HUMANS; LEVODOPA; N-METHYL-3,4-METHYLENEDIOXYAMPHETAMINE; STEREOISOMERISM; TOXICITY TESTS;

BACTERIA (MICROORGANISMS); ESCHERICHIA COLI;

EID: 75149197655     PISSN: 0893228X     EISSN: 15205010     Source Type: Journal    
DOI: 10.1021/tx9003374     Document Type: Article

References (50)

1. Milroy, C. M., Clark, J. C., and Forrest, A. R. W. (1996) Pathology of deaths associated with "ecstasy" and "eve" misuse. J. Clin. Pathol. 49, 149-153.
2. Walubo, A., and Seger, D. (1999) Fatal multi-organ failure after suicidal overdose with MDMA, "ecstasy": case report and review of the literature. Hum. Exp. Toxicol. 18, 119-125.
3. Fineschi, V., Centini, F., Mazzeo, E., and Turillazzi, E. (1999) Adam (MDMA) and Eve (MDA) misuse: an immunohistochemical study on three fatal cases. Forensic Sci. Int. 104, 65-74.
4. Cole, J. C., and Sumnall, H. R. (2003) Altered states: the clinical effects of ecstasy. Pharmacol. Ther. 98, 35-58.
5. Ricaurte, G. A., and McCann, U. D. (2005) Recognition and management of complications of new recreational drug use. Lancet 365, 2137-2145.
6. Green, A. R., Mechan, A. O., Elliot, J. M., O'Shea, E., and Colado, M. I. (2003) The pharmacology and clinical pharmacology of 3,4- methylenedioxymethamphetamine (MDMA, "ecstasy"). Pharmacol. Rev. 55, 463-508, and references therein.
7. Lyles, J., and Cadet, J. L. (2003) Methylenedioxymethamphetamine (MDMA, Ecstasy) neurotoxicity: cellular and molecular mechanisms. Brain Res. Rev. 42, 155-168, and references therein.
8. Morton, J. (2005) Ecstasy: pharmacology and neurotoxicity. Curr. Opin. Pharmacol. 5, 79-86.
9. Baumann, M. H., Wang, X., and Rothman, R. B. (2007) 3,4- methylenedioxymethamphetamine (MDMA) neurotoxicity in rats: a reappraisal of past and present findings. Psychopharmacology 189, 407-424.
10. De Win, M. M. L., Jager, G., Booij, J., Reneman, L., Schilt, T., Lavini, C., Olabarriaga, S. D., den Heeten, G. J., and van den Brink, W. (2008) Sustained effects of ecstasy on the human brain: a prospective neuroimaging study in novel users. Brain 131, 2936-2945.
11. Gudelsky, G. A., and Yamamoto, B. K. (2008) Action of 3,4-methylenedioxymethamphetamine (MDMA) on cerebral dopaminergic, serotonergic and cholinergic neurons. Pharmacol., Biochem. Behav. 90, 198-207.
12. Capela, J. P., Carmo, H., Remiao, F., Lourdes Bastos, M., Meisel, A., and Carvalho, F. (2009) Molecular and cellular mechanisms of ecstasy-induced neurotoxicity: an overview. Mol. Neurobiol. 39, 210-271, and references therein.
13. Goni-Allo, B., Puerta, E., Mathuna, B. O., Hervias, I., Lasheras, B., de la Torre, R., and Aguirre, N. (2008) On the role of tyrosine and peripheral metabolism in 3,4-methylenedioxymethamphetamine-induced serotonin neurotoxicity in rats. Neuropharmacology 54, 885-900.
14. Esteban, B., O'Shea, E., Camarero, J., Sanchez, V., Green, A. R., and Colado, M. I. (2001) 3,4-Methylenedioxymethamphetamine induces monoamine release, but not toxicity, when administered centrally at a concentration occurring following a peripherally injected neurotoxic dose. Psychopharmacology 154, 251-260.
15. Monks, T. J., Jones, D. C., Bai, F., and Lau, S. S. (2004) The role of metabolism in 3, 4-(±)-methylenedioxyamphetamine and 3,4-(±)- methylenedioxymethamphetamine (Ecstasy) toxicity. Ther. Drug Monit. 26, 132-136.
16. Segura, M., Jordi, O., Farré, M., McLure, J. A., Pujadas, M., Pizarro, N., Llebaria, A., Joglar, J., Roset, P. N., Segura, J., and de la Torre, R. (2001) 3,4-Dihydroxymethamphetamine (HHMA). A major in vivo 3, 4-methylenedioxymethamphetamine (MDMA) metabolite in humans. Chem. Res. Toxicol. 14, 1203-1208.
17. Perfetti, X., O'Mathuna, B., Pizarro, N., Cuyas, E., Khymenets, O., Almeida, B., Pellegrini, M., Pichini, S., Lau, S. S., Monks, T. J., Farré, M., Pascual, J. A., Joglar, J., and de La Torre, R. (2009) Neurotoxic thioether adducts of 3,4-methylenedioxymethamphetamine identified in human urine after ecstasy ingestion. Drug Metab. Dispos. 37, 1448-1455.
18. Felim, A., Urios, A., Neudörffer, A., Herrera, G., Blanco, M., and Largeron, M. (2007) Bacterial plate assays and electrochemical methods: an efficient tandem for evaluating the ability of catecholthioether metabolites of MDMA ("ecstasy") to induce toxic effects through redox-cycling. Chem. Res. Toxicol. 20, 685-693.
19. Mueller, M., Yuan, J., Felim, A., Neudörffer, A., Peters, F. T., Maurer, H. H., McCann, U. D., Largeron, M., and Ricaurte, G. A. (2009) Further studies on the role of metabolites in (±)-3,4- methylenedioxymethamphetamine-induced serotonergic neurotoxicity. Drug Metab. Dispos. 37, 2079-2086.
20. Jones, D. C., Duvauchelle, C., Ikegami, A., Olsen, C. M., Lau, S. S., de la Torre, R., and Monks, T. J. (2005) Serotonergic neurotoxic metabolites of ecstasy identified in rat brain. J. Pharmacol. Exp. Ther. 313, 422-431.
21. Erives, G. V., Lau, S. S., and Monks, T. J. (2008) Accumulation of neurotoxic thioether metabolites of 3,4-(±)-methylenedioxymethamphetamine in rat brain. J. Pharmacol. Exp. Ther. 324, 284-291.
22. Pizarro, N., de la Torre, R., Joglar, J., Okumura, N., Perfetti, X., Lau, S. S., and Monks, T. J. (2008) Serotonergic neurotoxic thioether metabolites of 3,4-methylenedioxymethamphetamine (MDMA, "ecstasy"): synthesis, isolation and characterization of diastereoisomers. Chem. Res. Toxicol. 21, 2272-2279.
23. Meyer, M. R., Peters, F. T., and Maurer, H. H. (2008) The role of human hepatic cytochrome P450 isoenzymes in the metabolism of racemic 3, 4-methylenedioxymethamphetamine and its enantiomers. Drug Metab. Dispos. 36, 2345-2354.
24. Anderson, G. M., Braun, G., Braun, U., Nichols, D. E., and Shulgin, A. T. (1978) Absolute Configuration and Psychotomimetic Activity, in Quasar Research Monograph 22 (Barnett, G., Trisc, M., and Willette, R., Eds.) pp 8-15, National Institute on Drug Abuse, Washington, DC.
25. Hiramatsu, M., Nabeshima, T., Kameyama, T., Maeda, Y., and Cho, A. K. (1989) The effect of optical isomers of 3,4-methylenedioxymethamphetamine (MDMA) on stereotyped behavior in rats. Pharmacol., Biochem. Behav. 33, 343-347.
26. 3H]dopamine release from superfused rat brain slices. Eur. J. Pharmacol. 132, 269-276.
27. Fantegrossi, W. E., Godlewski, T., Karabenick, R. L., Stephens, J. M., Ullrich, T., Rice, K. C., and Woods, J. H. (2003) Pharmacological characterization of the effects of 3,4-methylenedioxymethamphetamine ("ecstasy") and its enantiomers on lethality, core temperature, and locomotor activity in singly housed and crowded mice. Psychopharmacology 166, 202-211.
28. Pizarro, N., Farré, M., Pujadas, M., Peiro, A. M., Poset, P. N., Joglar, J., and de la Torre, R. (2004) Stereochemical analysis of 3,4-methylenedioxymethamphetamine and its main metabolites in human samples including the catechol-type metabolite (3,4-dihydroxymethamphetamine). Drug Metab. Dispos. 32, 1001-1007.
29. Fantegrossi, W. E. (2008) In vivo pharmacology of MDMA and its enantiomers in rhesus monkeys. Exp. Clin. Psychopharmacol. 16, 1-12, and references therein.
30. Fantegrossi, W. E., Murai, N., Mathuna, B. O., Pizarro, N., and de la Torre, R. (2009) Discriminative stimulus effects of MDMA and its enantiomers in mice: pharmacokinetic considerations. J. Pharmacol. Exp. Ther. 329, 1006-1015.
31. Felim, A., Neudörffer, A., Monnet, F. P., and Largeron, M. (2008) Environmentally friendy expeditious one-pot electrochemical synthesis of bis-catechol-thioether metabolites of ecstasy: in vitro neurotoxic effects in the rat hippocampus. Int. J. Electrochem. Sci. 3, 266-281.
32. Macedo, C., Branco, P. S., Ferreira, L. M., Lobo, A. M., Capela, J. P., Fernandes, E., de Lourdes Bastos, M., and Carvalho, F. (2007) Synthesis and cyclic voltammetry studies of 3,4-methylenedioxymethamphetamine (MDMA) human metabolites. J. Health Sci. 53, 31-42.
33. Pizarro, N., de la Torre, R., Farré, M., Segura, J., Llebaria, A., and Joglar, J. (2002) Synthesis and capillary electrophoretic analysis of enantiomerically enriched reference standards of MDMA and its main metabolites. Bioorg. Med. Chem. 10, 1085-1092.
34. + parent WP2 uvrA/pKM101: detection of 31 oxidative mutagens. Mutat. Res. 467, 41-53.
35. Morgan, P. H., and Beckett, A. H. (1975) Synthesis of some N-oxygenated products of 3,4-dimethoxyamphetamine and its N-alkyl derivatives. Tetrahedron 31, 2595-2601.
36. Borgman, R. J., Baylor, M. R., McPhillips, J. J., and Stitzel, R. E. (1974) α-Methyldopamine derivatives. Synthesis and pharmacology. J. Med. Chem. 17, 427-430.
37. Cannon, J. G., Perez, Z., Long, J. P., Rusterholtz, D. B., Flynn, J. R., Costall, B., Fortune, D. H., and Naylor, R. J. (1979) N-alkyl derivatives of (±)-α-methyldopamine. J. Med. Chem. 22, 901-907.
38. Milhazes, N., Cunha-Oliveira, T., Martins, P., Garrido, J., Oliveira, C., Rego, A. C., and Borges, F. (2006) Synthesis and cytotoxic profile of 3,4-methylenedioxymethamphetamine ("ecstasy") and its metabolites on undifferentiated PC12 cells: a putative structure-toxicity relationship. Chem. Res. Toxicol. 19, 1294-1304.
39. X) of the benzylic position as a tunable synthesis of tetrahydroisoquinoline natural alkaloid analogues. Eur. J. Org. Chem. 5212-5225.
40. 3 peptide mimetic aldehyde calpain I inhibitors. J. Med. Chem. 44, 3488-3503.
41. Tang, S., Martinez, L. J., Sharma, A., and Chai, M. (2006) Synthesis and characterization of water-soluble and photostable L-DOPA dendrimers. Org. Lett. 8, 4421-4424.
42. 3 receptors. A promising antidiabetic and antiobesity agent. J. Med. Chem. 35, 3081-3084.
43. Garcia, E., Arrasate, S., Lete, E., and Sotomayor, N. (2005) Diastereoselective intramolecular α-amidoalkylation reactions of L-DOPA derivatives. Asymmetric synthesis of pyrrolo[2,1-a]isoquinolines. J. Org. Chem. 70, 10368-10374.
44. Clark, R. D., Berger, J., Lee, C.-H., and Muchowski, J. M. (1987) Synthesis and determination of the absolute stereochemistry of the enantiomers of 3-substituted 1,2,3,4-tetrahydroisoquinolines related to the calcium antagonist verapamil. Heterocycles 26, 1290-1302.
45. Darzynkiewicz, Z., Juan, G., Li, X., Gorczyca, W., Murakami, T., and Traganos, F. (1997) Cytometry in cell necrobiology: analysis of apoptosis and accidental cell death (necrosis). Cytometry 27, 1-20.
46. Gomez-Santos, C., Ferrer, I., Santidrian, A. F., Barrachina, M., Gil, J., and Ambrioso, S. (2003) Dopamine induces autophagic cell death and α-synuclein increase in human neuroblastoma cells. J. Neurosci. Res. 73, 341-350.
47. Haque, M. E., Asanuma, M., Higashi, Y., Miyazaki, I., Tanaka, K.-I., and Ogawa, N. (2003) Apoptosis-inducing neurotoxicity of dopamine and its metabolites via reactive quinone generation in neuroblastoma cells. Biochim. Biophys. Acta 1619, 39-52.
48. Urios, A., Largeron, M., Fleury, M.-B., and Blanco, M. (2006) A convenient approach for evaluating the toxicity profiles of in vitro neuroprotective alkylaminophenol derivatives. Free Radical Biol. Med. 40, 791-800.
49. Urios, A., López-Gresa, M. P., González, M. C., Primo, J., Martinez, A., Herrera, G., Escubedo, J. C., O'Connor, J. E., and Blanco, M. (2003) Nitric oxide promotes strong cytotoxicity of phenolic compounds against Escherichia coli: the influence of antioxidant defenses. Free Radical Biol. Med. 35, 1373-1381.
50. Meyer, M. R., and Maurer, H. H. (2009) Enantioselectivity in the methylation of the catecholic phase I metabolites of methylenedioxy designer drugs and their capability to inhibit catechol-O-methyltransferase-catalyzed dopamine 3-methylation. Chem. Res. Toxicol. 22, 1205-1211.